Retatrutide tracker

Retatrutide is an investigational triple agonist currently in phase 3 clinical development, targeting GLP-1, GIP, and glucagon receptors simultaneously. This multi-receptor engagement is hypothesised to produce additive or synergistic effects on energy balance, glucose metabolism, and body composition beyond what dual agonists achieve. Early-phase trials have shown substantial weight reduction and HbA1c improvement. With a half-life of approximately 144 hours and a Tmax of around 36 hours, it is designed for once-weekly subcutaneous administration. As an investigational compound, its long-term safety profile is still being characterised, making systematic side-effect and dose tracking especially important for early adopters enrolled in clinical protocols.